A two-drug boost: combining GLP-1s with NB-ER for tougher-to-treat obesity
A new review suggests that for people who don’t respond to GLP-1 weight-loss drugs, adding NB-ER (naltrexone/bupropion) may improve outcomes by reducing hunger and cravings. Genetics may explain nonresponse, and experts say a multi-pronged, personalized approach could help some patients who fail to reach meaningful weight loss with GLP-1 alone.